Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

BACKGROUND: Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related quality of life and very high cost. Several small studies fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Ehab, Schiffer, Charles A., Weinfurt, Kevin P., Zhang, Mei-Jie, Radich, Jerald P., Oehler, Vivian G., Pinilla-Ibarz, Javier, Deininger, Michael W. N., Lin, Li, Larson, Richard A., Mauro, Michael J., Moore, Joseph O., Ritchie, Ellen K., Shah, Neil P., Silver, Richard T., Wadleigh, Martha, Cortes, Jorge, Thompson, James, Guhl, Jessica, Horowitz, Mary M., Flynn, Kathryn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879565/
https://www.ncbi.nlm.nih.gov/pubmed/29609532
http://dx.doi.org/10.1186/s12885-018-4273-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879565/
https://www.ncbi.nlm.nih.gov/pubmed/29609532
http://dx.doi.org/10.1186/s12885-018-4273-1

Ejemplares similares